These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32538847)

  • 1. Individual Brain Metabolic Signatures in Corticobasal Syndrome.
    Cerami C; Dodich A; Iannaccone S; Magnani G; Marcone A; Guglielmo P; Vanoli G; Cappa SF; Perani D
    J Alzheimers Dis; 2020; 76(2):517-528. PubMed ID: 32538847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder.
    Borroni B; Premi E; Agosti C; Alberici A; Cerini C; Archetti S; Lanari A; Paghera B; Lucchini S; Caimi L; Padovani A
    J Neurol Neurosurg Psychiatry; 2011 Aug; 82(8):834-8. PubMed ID: 21345847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinico-metabolic correlates of language impairment in corticobasal syndrome and progressive supranuclear palsy.
    Dodich A; Cerami C; Inguscio E; Iannaccone S; Magnani G; Marcone A; Guglielmo P; Vanoli G; Cappa SF; Perani D
    Neuroimage Clin; 2019; 24():102009. PubMed ID: 31795064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome.
    Parmera JB; Coutinho AM; Aranha MR; Studart-Neto A; de Godoi Carneiro C; de Almeida IJ; Fontoura Solla DJ; Ono CR; Barbosa ER; Nitrini R; Buchpiguel CA; Brucki SMD
    Mov Disord; 2021 Mar; 36(3):651-661. PubMed ID: 33206389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET patterns associated with underlying pathology in corticobasal syndrome.
    Pardini M; Huey ED; Spina S; Kreisl WC; Morbelli S; Wassermann EM; Nobili F; Ghetti B; Grafman J
    Neurology; 2019 Mar; 92(10):e1121-e1135. PubMed ID: 30700592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and Structural Signatures of Speech and Language Impairment in Corticobasal Syndrome: A Multimodal PET/MRI Study.
    Parmera JB; de Almeida IJ; de Oliveira MCB; Silagi ML; de Godoi Carneiro C; Studart-Neto A; Ono CR; Reis Barbosa E; Nitrini R; Buchpiguel CA; Brucki SMD; Coutinho AM
    Front Neurol; 2021; 12():702052. PubMed ID: 34526958
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
    Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
    Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, neuropsychological and imaging characteristics of Alzheimer's disease patients presenting as corticobasal syndrome.
    Constantinides VC; Paraskevas GP; Efthymiopoulou E; Stefanis L; Kapaki E
    J Neurol Sci; 2019 Mar; 398():142-147. PubMed ID: 30711771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers.
    Vasilevskaya A; Taghdiri F; Multani N; Anor C; Misquitta K; Houle S; Burke C; Tang-Wai D; Lang AE; Fox S; Slow E; Rusjan P; Tartaglia MC
    Front Neurol; 2020; 11():574. PubMed ID: 32754109
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.
    VandeVrede L; La Joie R; Thijssen EH; Asken BM; Vento SA; Tsuei T; Baker SL; Cobigo Y; Fonseca C; Heuer HW; Kramer JH; Ljubenkov PA; Rabinovici GD; Rojas JC; Rosen HJ; Staffaroni AM; Boeve BF; Dickerson BC; Grossman M; Huey ED; Irwin DJ; Litvan I; Pantelyat AY; Tartaglia MC; Dage JL; Boxer AL
    JAMA Neurol; 2023 May; 80(5):495-505. PubMed ID: 37010841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET-based classification of corticobasal syndrome.
    Nakano Y; Shimada H; Shinotoh H; Hirano S; Tagai K; Sano Y; Yamamoto Y; Endo H; Matsuoka K; Takahata K; Kubota M; Takado Y; Kimura Y; Ichise M; Ono M; Sahara N; Kawamura K; Zhang MR; Kuwabara S; Suhara T; Higuchi M
    Parkinsonism Relat Disord; 2022 May; 98():92-98. PubMed ID: 35533530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.
    Garcia-Cordero I; Anastassiadis C; Khoja A; Morales-Rivero A; Thapa S; Vasilevskaya A; Davenport C; Sumra V; Couto B; Multani N; Taghdiri F; Anor C; Misquitta K; Vandevrede L; Heuer H; Tang-Wai D; Dickerson B; Pantelyat A; Litvan I; Boeve B; Rojas JC; Ljubenkov P; Huey E; Fox S; Kovacs GG; Boxer A; Lang A; Tartaglia MC;
    Ann Neurol; 2024 Jul; 96(1):99-109. PubMed ID: 38578117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity of cingulate-precuneus-temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer's Disease.
    Isella V; Crivellaro C; Formenti A; Musarra M; Pacella S; Morzenti S; Ferri F; Mapelli C; Gallivanone F; Guerra L; Appollonio I; Ferrarese C
    J Neurol; 2022 Aug; 269(8):4440-4451. PubMed ID: 35347453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Liu FT; Lu JY; Li XY; Jiao FY; Chen MJ; Yao RX; Liang XN; Ju ZZ; Ge JJ; Li G; Shen B; Wu P; Song J; Li J; Sun YM; Wu JJ; Yen TC; Luo JF; Zhao QH; Zuo C; Wang J;
    Mov Disord; 2023 Apr; 38(4):579-588. PubMed ID: 36750757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroimaging in corticobasal syndrome].
    Shinotoh H
    Rinsho Shinkeigaku; 2013; 53(11):1029-32. PubMed ID: 24291869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.